TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1380148
Drug: CODE chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CODE chemotherapy with recombinant human granulocyte colony-stimulating factor
Study: 1380148
Drug: CODE chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CODE chemotherapy without recombinant human granulocyte colony-stimulating factor
Study: 29505471
Drug: GSK561679 (CRHR1
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK561679 (CRHR1 antagonist)
Study: 27178257
Drug: DAGR 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAGR 1 mg QD
Study: 27178257
Drug: DAGR 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAGR 5 mg QD
Study: 27178257
Drug: DAGR 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAGR 10 mg QD
Study: 27178257
Drug: DAGR 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAGR 15 mg QD
Study: 27178257
Drug: DAGR 9
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAGR 9 mg QD
Study: 27178257
Drug: Prednisone 5
Normalized name: prednisone 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 5 mg QD
Study: 27178257
Drug: Prednisone 10
Normalized name: prednisone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 10 mg QD
Study: 16385833
Drug: Single-dose internal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose internal brachytherapy (12 Gy)
Study: 9279536
Drug: euglycaemic hyperinsulinaemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: euglycaemic hyperinsulinaemia (HI) with plasma insulin at 80 mUL‐1 and glucose at 4‐5 mmolL‐1
Study: 6882619
Drug: Ibopamine 200
Normalized name: ibopamine
DrugBank: Ibopamine (DB13316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibopamine 200 mg
Study: 3209280
Drug: Furosemide 40
Normalized name: furosemide 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 40 mg plus Ibopamine 200 mg
Study: 11714065
Drug: Terbinafine 1%
Normalized name: Terbinafine 1% Topical application Gel/Jelly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 1% cream, applied once daily for 7 days
Study: 29550384
Drug: Reduced-intensity conditioning
Normalized name: ALLANTOIN 1 g in 100 g TOPICAL CREAM [Scar Reducer Intensive Herbal and Nutrient]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-intensity conditioning (120 mg/m2 fludarabine + 4 doses of 2 Gy total-body irradiation)
Study: 29550384
Drug: Myeloablative conditioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myeloablative conditioning (6 doses of 2 Gy total-body irradiation + 120 mg/kg cyclophosphamide)
Study: 25154982
Drug: Bevacizumab 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 7.5 mg/kg or 15 mg/kg plus chemotherapy
Study: 20818474
Drug: BCAAs supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAAs supplementation (0.4 g/kg/day and 0.2 g/kg/day)
Study: 17362472
Drug: Budesonide/formoterol 160/4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol 160/4.5 microg one inhalation bid plus additional inhalations as needed
Study: 17362472
Drug: Fixed-dose budesonide/formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose budesonide/formoterol 320/9 microg one inhalation bid plus as-needed terbutaline
Study: 15102873
Drug: Intravenous palonosetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous palonosetron (0.3 to 90 microg/kg)
Study: 24587006
Drug: Intravenous palonosetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous palonosetron
Study: 11581434
Drug: Educational video
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational video intervention (20-minute video and brochure about antibiotics)
Study: 9704672
Drug: Three-drug combination
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-drug combination of docetaxel (75 mg/m2), ifosfamide (3,000 mg/m2), and cisplatin (75 mg/m2) with lenograstim support
Study: 9704672
Drug: Three-drug combination
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-drug combination of docetaxel, ifosfamide, and cisplatin
Study: 7991433
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation with iron sulfate 5 mg/kg until day 56
Study: 2567483
Drug: Sotalol (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol (320 mg.d‐1)
Study: 2567483
Drug: Propranolol (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (160 mg.d‐1)
Study: 2567483
Drug: Atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (100 mg.d‐1)
Study: 5124439
Drug: Pyrantel embonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrantel embonate 100 mg/kg
Study: 5124439
Drug: Pyrantel embonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrantel embonate 75 mg/kg
Study: 5124439
Drug: Pyrantel embonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrantel embonate 50 mg/kg
Study: 5124439
Drug: Pyrantel embonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrantel embonate 20 mg/kg
Study: 5124439
Drug: Pyrantel embonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrantel embonate 15 mg/kg
Study: 5124439
Drug: Pyrantel embonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrantel embonate 10 mg/kg
Study: 28627029
Drug: Test cream
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test cream (moisturizer containing urea, glycerine, and petrolatum)
Study: 23792400
Drug: Four bar-connected
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four bar-connected implants
Study: 23792400
Drug: Six bar-connected
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Six bar-connected implants
Study: 22013797
Drug: Reduning Injection
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduning Injection (RI)
Study: 22013797
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Reduning Injection with Ribavirin Injection or antibiotics
Study: 15072892
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (gonadotropin‐releasing hormone agonist or bilateral orchiectomy)
Study: 11424777
Drug: Meperidine 75
Normalized name: MEPERIDINE 75MG/ML INJ CARPUJECT LL 1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 75 mg i.m.
Study: 11424777
Drug: Tramadol 100
Normalized name: tramadol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 100 mg i.m.
Study: 9105521
Drug: High-dose immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose immunotherapy (HDI) group (MTD >= 4 micrograms Der p 1)
Study: 9105521
Drug: Conventional immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional immunotherapy (CI) group (MTD < 4 micrograms Der p 1)
Study: 8394858
Drug: Intravenous ganciclovir,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ganciclovir, 5 mg/kg twice daily for 14 days followed by 5 mg/kg once daily for 14 weeks
Study: 8394858
Drug: Deferred treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred treatment (control)
Study: 2941267
Drug: Stepped care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped care antihypertensive therapy
Study: 23039014
Drug: Garlic tablets
DrugBank: Garlic (DB10532)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic tablets (2 tablets daily for 1 month)
Study: 23039014
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets (2 tablets daily for 1 month)
Study: 19253204
Drug: Sitagliptin 50
Normalized name: SITagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 50 mg b.i.d.
Study: 18353996
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg b.i.d.
Study: 10064669
Drug: TTS-fentanyl (transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTS-fentanyl (transdermal fentanyl system)
Study: 7586783
Drug: Azapropazone (APZ)
Normalized name: azapropazone
DrugBank: Azapropazone (DB07402)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azapropazone (APZ) 300 mg t.i.d. for three weeks
Study: 2405747
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide aerosol (25 mg per actuation, qid, for 4 weeks)
Study: 29210815
Drug: Advice from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advice from home care nurses on fiber intake, liquid intake, mobilization, laxative administration, and physician referral
Study: 26373705
Drug: Laxative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laxative therapy (lactulose and enemas)
Study: 15223721
Drug: Newer drugs
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Newer drugs (ACE inhibitors, calcium antagonists)
Study: 15223721
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (diuretics, beta-blockers)
Study: 9161624
Drug: Ondansetron 32
Normalized name: ondansetron 32 MG in 50 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 32 mg i.v. over 15 minutes
Study: 3508564
Drug: Three production
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three production lots of macrocrystalline nitrofurantoin capsules (Macrodantin)
Study: 3508564
Drug: Capsules from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules from one production lot administered on three occasions
Study: 25992866
Drug: Postoperative cold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative cold patch
Study: 25992866
Drug: Wash group
Normalized name: Zencia Wash
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wash group (ice-cold balanced salt solution)
Study: 22616762
Drug: SRT2104 (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRT2104 (doses ranging from 0.03 to 3.0 g)
Study: 22303708
Drug: Probucol Tablet
Normalized name: Probucol Tablets
DrugBank: Probucol (DB01599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Probucol Tablet (PT) 0.5 g, twice daily
Study: 22303708
Drug: Lumbrukinase Capsule
Normalized name: lumbrokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbrukinase Capsule (LC) 600 thousand U, thrice daily + Probucol Tablet (PT)
Study: 14982689
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg nicotine
Study: 14982689
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg nicotine
Study: 14982689
Drug: Repeated dosing
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated dosing with The Straw
Study: 11502768
Drug: 131I plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 131I plus pretreatment with methimazole (30 mg/d)
Study: 9248982
Drug: Postoperative antiprostaglandins
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative antiprostaglandins and H2-blockers
Study: 3777409
Drug: Nalbuphine 10
Normalized name: nalbuphine 10 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 10 mg
Study: 3544982
Drug: Nalbuphine 10
Normalized name: nalbuphine 10 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 10 mg plus Hydroxyzine 50 mg
Study: 24838062
Drug: Cryotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryotherapy and BSS-BSSG mixture (20 mg sterol and 0.2 mg sterolin)
Study: 21086166
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg bid for 1 week
Study: 16937744
Drug: 3-3 group,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-3 group, 1 drop 3 times daily for 2 years
Study: 16937744
Drug: 2-3 group,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-3 group, 1 drop twice daily in year 1 and 1 drop 3 times daily in year 2
Study: 16937744
Drug: 1-3 group,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-3 group, 1 drop once daily in year 1 and 1 drop 3 times daily in year 2
Study: 10374174
Drug: Control group,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group, no treatment
Study: 7492863
Drug: Chlorthalidone (12.5-25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (12.5-25 mg/day)
Study: 6803944
Drug: Azathioprine (2-2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (2-2.5 mg/kg body weight over six months)
Study: 25069770
Drug: Milbemax® (milbemycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milbemax® (milbemycin oxime/praziquantel) at a minimum target dose of 0.5 mg/kg bodyweight and 5 mg/kg bodyweight respectively, administered once every 4 weeks.
Study: 25069770
Drug: Untreated group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Untreated group (T2) receiving specific parasiticide treatments when necessary.
Study: 22705017
Drug: Non-prescribed Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-prescribed Chinese herbal medicine (CHM)
Study: 18382796
Drug: Fentanyl 25
Normalized name: FENTANYL 25MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 25 micrograms with midazolam 1 mg IV
Study: 18382796
Drug: Remifentanil 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0.3 microgram/kg with midazolam 1 mg IV
Study: 15755572
Drug: HIV plasmid
Normalized name: plasmin
DrugBank: Fibrinolysin (DB05254)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV plasmid vaccine (combination of two HIV DNA plasmid constructs)
Study: 15755572
Drug: HIV plasmid
Normalized name: plasmin
DrugBank: Fibrinolysin (DB05254)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV plasmid vaccine
Study: 12093983
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (emollients and topical corticosteroids)
Study: 9585803
Drug: Oral artemisinin
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral artemisinin (500 mg daily)
Study: 9585803
Drug: Rectal artemisinin
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal artemisinin (500 mg daily)
Study: 9585803
Drug: Rectal artemisinin
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal artemisinin
Study: 9585803
Drug: Oral artemisinin
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral artemisinin
Study: 3525317
Drug: Levamisole (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (150 mg/day, 3 days/week)
Study: 29790612
Drug: 0.5 MHz,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 MHz, invasive, bipolar RF treatment with longer conduction time and lower power (LC/LP)
Study: 29790612
Drug: 0.5 MHz,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 MHz, invasive, bipolar RF treatment with shorter conduction time and higher power (SC/HP)
Study: 23678153
Drug: delayed golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: delayed golimumab treatment (Group 1)
Study: 788820
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g ascorbic acid per day
Study: 19818690
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g ascorbic acid per day
Study: 9145445
Drug: Lactulose (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose (2 x 10 g/d)
Study: 9145445
Drug: Lactitol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactitol (2 x 10 g/d)
Study: 2122422
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of aminophylline
Study: 2122422
Drug: Phase 1
Normalized name: Coxiella burnetii phase 1 IgA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 1 (Theo-24 6 mg/kg with 100 ml of water)
Study: 690225
Drug: Systems Releasing
Normalized name: Vaginal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systems Releasing Action Therapy (SRAT)
Study: 29306232
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate 100 μg per day
Study: 29306232
Drug: Montelukast 4/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 4/5 mg per day
Study: 24823842
Drug: Tobacco Tactics
Normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobacco Tactics intervention (nurse counseling, brochure, DVD, manual, pharmaceuticals, 1‐800‐QUIT‐NOW card, post‐discharge telephone calls)
Study: 20558967
Drug: Strength training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength training conducted twice a week for 12 weeks.
Study: 18182669
Drug: Reduced induction
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced induction therapy (no anthracyclines) for SR patients
Study: 18182669
Drug: Conventional BFM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional BFM schedule intensified with three chemotherapy blocks followed by a double reinduction phase for HR patients
Study: 10384893
Drug: Noise exposure
Normalized name: Anthrax, post-exposure prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noise exposure with stimulus combination L1 = 65 dB, L1‐L2 = 25 dB, f2/f1 = 1.18
Study: 6766653
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (40 mg four times daily for 3 months)
Study: 6766653
Drug: Placebo (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (40 mg four times daily for 3 months)
Study: 30822774
Drug: F17464, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: F17464, 20 mg twice daily
Study: 25540069
Drug: Intraoperative morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative morphine guided by ANI
Study: 25540069
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (intraoperative morphine guided by anaesthetist with ANI concealed)
Study: 23993224
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg intravenous ketorolac preoperatively
Study: 21813441
Drug: Active training
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active training treatment (strength training)
Study: 15099455
Drug: Home-administered influenza
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-administered influenza vaccination
Study: 11309872
Drug: Inhalation sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation sedation (IHS)
Study: 9343033
Drug: Oral propafenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propafenone (600 mg loading dose)
Study: 8201510
Drug: Modified bovine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified bovine lung surfactant extract (beractant), 4 doses
Study: 2906778
Drug: Lormetazepam (sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lormetazepam (sublingual administration)
Study: 28972663
Drug: Daylight photodynamic
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daylight photodynamic therapy (DLPDT)
Study: 28972663
Drug: Conventional photodynamic
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional photodynamic therapy (CPDT)
Study: 27547851
Drug: G1 (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: G1 (twice a week plyometric training)
Study: 27547851
Drug: G2 (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: G2 (twice a week plyometric training)
Study: 25062570
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral nutritional supplements
Study: 25062570
Drug: Traditional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatment with water or lemonade
Study: 3912186
Drug: Bambuterol 30
Normalized name: bambuterol
DrugBank: Bambuterol (DB01408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bambuterol 30 mg administered once daily before going to bed
Study: 3912186
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release terbutaline 10 mg twice daily
Study: 3912186
Drug: Bambuterol 30
Normalized name: bambuterol
DrugBank: Bambuterol (DB01408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bambuterol 30 mg administered once daily
Study: 29144535
Drug: Waitlist control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waitlist control (WLC) with unrestricted access to treatment as usual
Study: 27421672
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: intravenous administration of contrast material at a dose of 1mL/kg and CTA examinations at 100kV
Study: 27421672
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: intravenous administration of contrast material at a dose of 0.5mL/kg and CTA examinations at 80kV
Study: 24045855
Drug: Protein drink
Normalized name: Boost High Protein Drink, Vanilla
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein drink containing 15 g protein, twice a day
Study: 24045855
Drug: Placebo drink,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drink, twice a day
Study: 26752109
Drug: Ebastine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebastine (20 mg/day)
Study: 12269645
Drug: Cetirizine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (10 mg/day)
Study: 15178915
Drug: Loratadine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine (10 mg/day)
Study: 8206064
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of piperacillin
Study: 8206064
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of piperacillin
Study: 2687897
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg bamyphylline
Study: 26053680
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus a hypocaloric diet for 6 months (group A)
Study: 20095806
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg glucocorticosteroids for 5 days